(Q37822453)

23 August 2017

1 reference

title

Respiratory syncytial virus disease: update on treatment and prevention (English)

1 reference

23 August 2017

Leonard R Krilov

1

1 reference

23 August 2017

publication date

1 January 2011

1 reference

Expert Review of Anti-infective Therapy

23 August 2017

published in

1 reference

23 August 2017

volume

9

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

27-32

1 reference

The burden of respiratory syncytial virus infection in young children

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Respiratory syncytial virus infection in elderly and high-risk adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Tucson Children's Respiratory Study: 1980 to present

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Diagnosis and management of bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Efficacy of beta2-agonists in bronchiolitis: a reappraisal and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Randomized, double-blind, placebo-controlled trial of oral albuterol in infants with mild-to-moderate acute viral bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

A multicenter, randomized, double-blind, controlled trial of nebulized epinephrine in infants with acute bronchiolitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Montelukast for respiratory syncytial virus bronchiolitis: significant effect or provocative findings?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Emerging drugs for respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Pharmacologic advances in the treatment and prevention of respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Respiratory syncytial virus (RSV) vaccines--two steps back for one leap forward.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.140

Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD000181.PUB2

Identifiers

DOI

10.1586/ERI.10.140

1 reference

23 August 2017

1 reference